Zolgensma: Bumpy Japan Review Holds Lessons For Applicants
‘Numerous And Extensive’ Problems
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
